Kenneth Blum^1,2*, Mark S Gold³, Catherine Dennen², Eric R. Braverman², David Baron¹, Panayotis K Thanos^4,5 and Rajendra D Badgaiyan⁶

¹Division of Addiction Research and Education, Center for Psychiatry, Medicine, and Primary Care (office of Provost), Western University Health Sciences, Pomona, CA, USA
²The Kenneth Blum Behavioral and Neurogenetic Institute, LLC, Austin, TX, USA
³Department of Psychiatry, Washington University School of Medicine, St. Louis, MO., USA
⁴Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York at Buffalo, Buffalo, NY, USA
⁵Department of Psychology, State University of New York at Buffalo, Buffalo, NY, USA
⁶Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, Long School of Medicine, University of Texas Medical Center, San Antonio, TX, USA

*Corresponding Author: Kenneth Blum, Division of Addiction Research and Education, Center for Psychiatry, Medicine, and Primary Care (office of Provost), Western University Health Sciences, Pomona, CA, USA and The Kenneth Blum Behavioral and Neurogenetic Institute, LLC, Austin, TX, USA.

Received: April 08, 2022; Published:

Abstract

Addiction clinicians and scientists face an enormous challenge in fighting the global opioid and alcohol use disorder (OUD/AUD) pandemics. Despite significant advances, the number of deaths attributed to narcotic overdose in the United States (US) alone exceeded 100,000 in 2021. The National Institute on Drug Abuse (NIDA) and The National Institute on Alcohol Abuse and Alcoholism (NIAAA) are struggling to generate novel approaches to tackle the severity of the present substance abuse epidemic.

References

1. Oesterle TS., et al. “Medication-Assisted Treatment for Opioid-Use Disorder”. Mayo Clinic Proceedings 94 (2019): 2072-2086.
2. Blum K., et al. “Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS)”. Journal of the Neurological Sciences 411 (2020): 116733.
3. Patterson Silver Wolf DA and Gold M. “Treatment resistant opioid use disorder (TROUD): Definition, rationale, and recommendations”. Journal of the Neurological Sciences 411 (2020):
4. Gold MS., et al. “Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?” Journal of the Neurological Sciences 418 (2020):
5. Downs BW., et al. “Death by Opioids: Are there non-addictive scientific solutions?” Journal of Systems and Integrative Neuroscience (2019): 5.
6. Blum K., et al. “Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual”. Journal of Systems and Integrative Neuroscience (2020): 7.
7. Morgan JR., et al. “Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population”. Journal of Substance Abuse Treatment 85 (2018): 90-96.
8. Ooteman W., et al. “Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators”. Addiction Biology 14 (2009): 328-337.
9. Cowen MS., et al. “The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system”.Addiction Biology 10 (2005): 233-242.
10. Gold MS., et al. “Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems”. Frontiers in Bioscience 10 (2018): 309-325.
11. Blum K., et al. “The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis”. Current Pharmaceutical Design 23 (2018): 6050-6061.
12. Blum K., et al. “Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind?” Journal of Personalized Medicine 2 (2022): 321.
13. Blum K., et al. “Coupling genetic addiction risk score (GARS) and pro dopamine regulation (KB220) to combat substance use disorder (SUD)”. Global Journal of Addiction and Rehabilitation Medicine
14. Gupta A., et al. “Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors”. International Journal of Environmental Research and Public Health 1 (2022): 552.

Citation

Citation: Kenneth Blum., et al. “Should We OPT to Induce “Dopamine Homeostasis” in the Long-Term Instead of Prescribing Powerful Opioids (Buprenorphine-Naloxone) to Treat Alcohol and Opioid use Disorders in the Face of the Drug Abuse Epidemic?". Acta Scientific Neurology 5.5 (2022): 00-00.

Copyright

Copyright: © 2022 Kenneth Blum., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.